Published in Ann N Y Acad Sci on May 13, 1998
Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci U S A (2008) 1.03
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science (1990) 4.01
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med (2000) 3.57
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A (1996) 3.07
Function and assembly of photosystem II: genetic and molecular analysis. Trends Biochem Sci (1988) 2.52
Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci (1976) 2.48
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med (1975) 2.43
Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med (1995) 2.32
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Immunoglobulins promote remyelination in the central nervous system. Ann Neurol (1990) 2.27
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med (1999) 2.12
tRNA genes as transcriptional repressor elements. Mol Cell Biol (1994) 2.10
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology (1998) 2.08
AmpG, a signal transducer in chromosomal beta-lactamase induction. Mol Microbiol (1993) 2.06
Heat shock regulatory gene rpoH mRNA level increases after heat shock in Escherichia coli. J Bacteriol (1986) 2.04
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology (1977) 1.78
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A (1999) 1.65
Cross-linking of IgE-receptor complexes at the cell surface: a fluorescence method for studying the binding of monovalent and bivalent haptens to IgE. Mol Immunol (1986) 1.65
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology (2011) 1.64
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med (1976) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology (1999) 1.52
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med (1978) 1.51
Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys J (1989) 1.47
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol (2013) 1.47
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology (1998) 1.46
1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.45
ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol (2001) 1.45
Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci (1976) 1.43
Seronegativity for type 1 antineuronal nuclear antibodies ('anti-Hu') in subacute sensory neuronopathy patients without cancer. Neurology (1993) 1.41
Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. J Immunol (1970) 1.39
Neurological autoimmunity targeting aquaporin-4. Neuroscience (2009) 1.39
New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol (2000) 1.38
Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature (1980) 1.38
Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol (2001) 1.36
The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies. Neurology (1994) 1.36
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother (1993) 1.33
Transitory expression of Thy-1 antigen in skeletal muscle development. Nature (1977) 1.32
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro. Proc Natl Acad Sci U S A (1978) 1.31
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci (1976) 1.30
Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve (1982) 1.28
Immunopharmacological disease: a break in tolerance to receptor sites. Lancet (1971) 1.23
Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J (2001) 1.21
End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci (1976) 1.21
Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord (1998) 1.20
Structure and variation of human ribosomal DNA: the external transcribed spacer and adjacent regions. Am J Hum Genet (1982) 1.19
Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc (1990) 1.19
Beta subunit heterogeneity in N-type Ca2+ channels. J Biol Chem (1996) 1.19
Brain-derived fibroblast growth factor: identity with a fragment of the basic protein of myelin. Proc Natl Acad Sci U S A (1978) 1.18
Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med (1986) 1.17
Revised 2.3 A structure of porcine pepsin: evidence for a flexible subdomain. Proteins (1990) 1.16
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun (1999) 1.11
Cross-linking of IgE-receptor complexes at the cell surface: synthesis and characterization of a long bivalent hapten that is capable of triggering mast cells and rat basophilic leukemia cells. Mol Immunol (1986) 1.11
Identification of three subunits of the high affinity omega-conotoxin MVIIC-sensitive Ca2+ channel. J Biol Chem (1996) 1.09
Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc (1992) 1.09
Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc (1998) 1.09
A chloroplast gene is required for the light-independent accumulation of chlorophyll in Chlamydomonas reinhardtii. EMBO J (1992) 1.09
Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci (2001) 1.08
Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology (2014) 1.08
Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol (1978) 1.08
Absence of cortical demyelination in neuromyelitis optica. Neurology (2010) 1.07
Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells. Neurology (1988) 1.07
Unlinked control of multiple glucocorticoid-induced processes in HTC cells. Mol Cell Endocrinol (1979) 1.07
Characterization of photosystem II mutants of Chlamydomonas reinhardii lacking the psbA gene. Plant Mol Biol (1986) 1.07
Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci (1987) 1.06
Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry (1998) 1.05
Sequence organization of repetitive elements in the flanking regions of the chloroplast ribosomal unit of Chlamydomonas reinhardii. Nucleic Acids Res (1985) 1.05
Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann N Y Acad Sci (1976) 1.05
Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. Biochem Biophys Res Commun (1990) 1.04
Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci U S A (1985) 1.04
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol (1996) 1.03
Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. Virology (1998) 1.02
Reduced muscle acetylcholine sensitivity in rats immunised with acetylcholine receptor. Nature (1976) 1.02
Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control. J Immunol (1979) 1.02
Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes. J Neuroimmunol (1988) 1.02
Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol (1987) 1.01
Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann N Y Acad Sci (1981) 1.01
Cytogenetic analysis of homozygous segregation distorter males of Drosophila melanogaster. Can J Genet Cytol (1976) 1.00